Nektar Therapeutics - Common Stock (NKTR)

The company reported that complete skin clearance rates increased twofold to fivefold during the maintenance phase of the trial.

Nektar announced positive results from the 36-week blinded maintenance period of the 52-week REZOLVE-AD study of its experimental drug, rezpegaldesleukin.

There is a key difference between these two biotechs.

When a biotech rallies nearly 200% and still gets trimmed, the real story likely isn’t about fear or a loss of conviction.

ANI is firing on all cylinders operationally, which makes this exit less about fundamentals and more about portfolio discipline at a moment when expectations might be sky-high.

Shares in the biotech company have surged on news of a big pharma takeover.

Nektar Therapeutics (NKTR) Q3 2025 results beat analyst estimates for both revenue and earnings per share, sending the stock higher in after-hours trading.

Is it too late to get on the bandwagon?

Results of the Resolve-AD trial with rezpegaldesleukin were better than expected.

Here's what needs to happen for these high flyers to continue soaring.

One of the company's pipeline drugs is showing significant promise.

Nektar reported Phase 2b results showing rezpegaldesleukin improved eczema severity scores and met primary and key secondary endpoints in patients.

The company's competitive positioning might be stronger now, after disappointing results from a key rival.

Nektar Therapeutics stock is trading higher with no news, possibly due to Sanofi's disappointing results.

The company said it has sufficient financial resources to fund its operations into early 2027.